Belharra Therapeutics Debuts With $130 Million in Funding

SAN MATEO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Belharra Therapeutics, Inc. today emerged from stealth mode with a novel photoaffinity-based chemoproteomics platform capable of identifying non-covalent, small molecule drug candidates for any protein. The company has secured $130 million in capital, including $50 million in Series A financing from founding investor Versant...

Click to view original post